vanillylmandelic acid

(redirected from Vanillyl mandelic acid)
Also found in: Wikipedia.

vanillylmandelic acid

 [vah-nil″il-man-del´-ik]
VMA; the primary end-product of catecholamine metabolism excreted in the urine. Urinary VMA levels are used in screening patients for pheochromocytoma.

va·nil·lyl·man·del·ic ac·id (VMA),

(vă-nil'il-man-del'ik as'id),
Misnomer for 4-hydroxy-3-methoxymandelic acid (α,3-dihydroxy-2-methoxybenzeneacetic acid); the major urinary metabolite of adrenal and sympathetic catecholamines (for example, from both epinephrine and norepinephrine); elevated in most patients with pheochromocytoma.

va·nil·lyl·man·del·ic ac·id

(VMA) (vă-nil'il-man-del'ik as'id)
The major urinary metabolite of adrenal and sympathetic catecholamines; elevated in most patients with pheochromocytoma.
References in periodicals archive ?
Twenty-four-hour urine collection revealed elevated vanillyl mandelic acid (VMA; 11.7 mg/day, reference: 2-7 mg/day), metanephrine (1625.6 [micro]g/day, reference: 52-341 [micro]g/day), normetanephrine (5459.5 [micro]g/day, reference: 88-444 [micro]g/day), epinephrine (256.4 [micro]g/day, reference: 0.20 [micro]g/day), and norepinephrine (153.2 [micro]g/day, reference: 15-80 [micro]g/day).
The preoperative diagnosis of pheochromocytoma is supported by elevated levels of urine and blood catecholamines and their metabolites, metanephrine and vanillyl mandelic acid (VMA).
Literature reports indicate that noradrenaline is released during stressful conditions and metabolised to vanillyl mandelic acid (VMA) peripherally and 3-methoxy 4-hydroxyphenyl glycol (MOPEG) centrally (Ion 1969, Fakuda 1996).